[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
chevron_left

IMS 2024

1. Highlights from IMS | Angela Dispenzieri, MD | IMS 2024 Video

bookmark_border

2. Thematic Analysis on Talquetamab and Patient Perceptions | Alexandra L. Greenwood, BSc | IMS 2024 Video

bookmark_border

3. Carfilzomib Dosing in the Real World Setting | Adeel Khan, MD | IMS 2024 Video

bookmark_border

4. New Criteria for Defining High Risk Multiple Myeloma | Gareth Morgan & Faith Davies | IMS 2024 Video

bookmark_border

5. Investigating Oral Toxicity Associated with Talquetamab in Myeloma | Rakesh Popat | IMS 2024 Video

bookmark_border
adjust

6. New IMS High Risk Multiple Myeloma Consensus Definition | Jill Corre, PharmD, PhD | IMS 2024 Video

bookmark_border

7. Treating High Risk Multiple Myeloma an Evidence-Based Approach | Katja Weisel, MD | IMS 2024 Video

bookmark_border

8. Safety and Efficacy of Cilta-Cel in RRMM: Real-World Experience | Surbhi Sidana, MD | IMS 2024 Video

bookmark_border

9. Iberdomide Maintenance Therapy after ASCT in Myeloma | Tanye Wildes, MD | IMS 2024 Video

bookmark_border

10. Current Approach for the Management of Smoldering Multiple Myeloma | Vincent Rajkumar, MD | IMS 2024 Video

bookmark_border

11. AURIGA- Dara + Len vs Len Alone as Myeloma Maintenance | Rafael Fonseca, MD | IMS 2024 Video

bookmark_border

12. Unveiling Novel Biomarkers in Myeloma: The Role of CTCs & cfDNA | Bruno Paiva, PhD | IMS 2024 Video

bookmark_border

13. Timing for Myeloma CAR-T Therapy: A Debate | Rahul Banerjee, MD and Sridevi Rajeeve, MD | IMS 2024 Video

bookmark_border

14. Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024 Video

bookmark_border

15. An Update on the Use of Bispecific Antibodies in Myeloma | Mohamad Mohty, MD | IMS 2024 Video

bookmark_border

16. Future Strategies for Managing 2nd Line+ Myeloma: What’s Next? | Leo Rasche, MD | IMS 2024 Video

bookmark_border

17. Preliminary Results of Mezigdomide Combinations in RRMM Patients | Luciano Costa, MD, PhD | IMS 2024 Video

bookmark_border

18. Real world evidence with teclistamab for RRMM patients | Bea Razzo, MD | IMS 2024 Video

bookmark_border

19. Optimizing Outcomes in Early CAR-T Therapy | Luciano Costa, MD, PhD | IMS 2024 Video

bookmark_border

20. Newer Therapies for RRMM: Impact on Aging Patients | Suzanne Lentzsch, MD, PhD | IMS 2024 Video

bookmark_border

21. Clinical Trial Results for Novel Academic Anti-BCMA Myeloma CAR-T Cell | Yael Cohen, MD | IMS 2024 Video

bookmark_border

22. Talquetamab and Teclistamab in RRMM: Updated Results from RedirecTT-1 | Yael Cohen, MD | IMS 2024 Video

bookmark_border

23. MILESTONE Trial: MRD Adapted Deferral of Transplant in Dysproteinemia | Susan Bal, MD | IMS 2024 Video

bookmark_border

24. Sequencing bispecific antibodies in myeloma - BCMA or GPRC5D? | Rahul Banerjee, MD | IMS 2024 Video

bookmark_border

25. Predictors of delayed responses to teclistamab in myeloma | Rahul Banerjee, MD | IMS 2024 Video

bookmark_border

26. Update on MCARH109- a GPRC5D CAR-T Cell for Myeloma | Eric Jergens, MD | IMS 2024 Video

bookmark_border

27. Linvoseltamab Efficacy in High-Risk RRMM: LINKER-MM1 Study | Attaya Suvannasankha, MD | IMS 2024 Video

bookmark_border

28. Efficacy of Bispecifics in Black Patients in Myeloma Trials | Craig Emmitt Cole, MD | IMS 2024 Video

bookmark_border

29. HealthTree Study: Dexamethasone's Impact on Eye Health in Myeloma | Rahul Banerjee, MD | IMS 2024 Video

bookmark_border

30. Real World Data on Ide-Cel Efficacy and Side Effects Profile | Rafat Abonour, MD | IMS 2024 Video

bookmark_border

31. Phase 3 Trials & Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | Bruno Costa, MD | IMS 2024 Video

bookmark_border

31. Positioning Model to Evaluate CARVYKTI in Second Line vs Later Lines | Rafael Fonseca, MD | IMS 2024 Video

bookmark_border

32. Selinexor Prior to CAR-T Cell Therapy in Myeloma | Bruno Costa, MD | IMS 2024 Video

bookmark_border

33. Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024 Video

bookmark_border

New IMS High Risk Multiple Myeloma Consensus Definition | Jill Corre, PharmD, PhD | IMS 2024

9 days ago